NanOlogy
  • Home
  • About
  • Technology
  • Development
    • Investigational Drugs
    • Pipeline
    • Clinical Trials
  • News & Publications
    • Recent News Highlights
    • Press Release Archives
    • NanOlogy In the News
    • Presentations & Publications Archive
  • Contact Us
    • Partnering Opportunities
    • Physicians and Patients
Post placeholder image
February 27, 2026 in NanOlogy Press Release

NanOlogy, LLC CEO David J. Arthur Discusses Their PURCISIONTM Technology Advancing Intratumoral Therapy to Treat Cancer

Wilson PJ 0 Like Post Comments Off on NanOlogy, LLC CEO David J. Arthur Discusses Their PURCISIONTM Technology Advancing Intratumoral Therapy to Treat Cancer
Read More
NanOlogy

NanOlogy investigational drugs have not yet been proven to be safe and effective in accordance with the requirements of the U.S. FDA and are not approved by FDA or any other jurisdiction for commercial distribution. NanOlogy, NanoPac, and NanoDoce are trademarks of NanOlogy, LLC.    Purcision is a trademark to CritiTech, Inc.  © NanOlogy LLC      Legal